EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

In Vivo Assessment of dbDNA GNE wt /bi‐shRNA‐GNE M743T Lipoplex for GNE Myopathy: Improved Potency and Safety

Christopher M Jay, Fabienne Kerneis, Donald Rao, Alexander Nemunaitis, Ernest Bognar, Gladice Wallraven, Laura Stanbery, Rebecca Lutz, Adam Walter, Sep Sarshar, John Nemunaitis

The Journal of Gene Medicine · 2026

DOI: 10.1002/jgm.70098 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Gene Medicine, 2026. Verfasst von Christopher M Jay und 10 weiteren Autor:innen. Beteiligte Einrichtung: Gradalis Inc, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Distal Myopathies, RNA, Small Interfering, Multienzyme Complexes, Genetic Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Solve GNE.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

GNE myopathy is an autosomal recessive disease, associated with skeletal muscle deterioration, which afflicts young adults. GNE plays a pivotal role in sialic acid production. Sialic acid acts as a buffer against reactive oxygen species generated during muscle contraction. Increased oxidative stress may relate to muscle atrophy involving patients with GNE myopathy. GNE M743T is the most common mutation leading to GNE myopathy. In our previous work, we demonstrated that a bifunctional plasmid that expresses wild type (wt) GNE and knocks down the GNE M743T mutant improves sialic acid production in vitro. Now, we expand evidence of in vivo activity of the bifunctional plasmid using a DOTAP‐Cholesterol delivery vehicle and reduced toxic plasmid components using dbDNA conversion. We demonstrate that IV delivery of dbDNA lipoplex (LPX) in murine and rat models shows safety, increased DNA delivery, and improved RNA expression per LPX in skeletal muscle over non db plasmid at equal dose. Sialic acid protein expression was also shown increased in mouse muscle following IV treatment with dbDNA plasmid (pDNA) GNE wt /bi‐shRNA‐GNE M743T LPX. These results support further preclinical investigation to justify product IND development towards Phase 1 trial involving patients with GNE myopathy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Distal MyopathiesRNA, Small InterferingMultienzyme ComplexesGenetic TherapyAnimalsMiceHumansPlasmidsMuscle, SkeletalRatsDisease Models, AnimalN-Acetylneuraminic AcidMaleLiposomes

Stichwörter der Autor:innen

GNEHIBMbi‐shRNAdbDNAdoggybone DNAlipoplex

Substanzen

RNA, Small InterferingMultienzyme ComplexesUDP-N-acetylglucosamine 2-epimerase - N-acetylmannosamine kinaseN-Acetylneuraminic AcidLiposomes

Autor:innen und Institutionen

  • Gradalis Inc, Dallas, Texas, USA.
  • Taylor Family Cancer Research Center, Maumee, Ohio, USA.
  • Promedica, Toledo, Ohio, USA.
  • Solve GNE, Los Angeles, California, USA.

Förderung

  • Solve GNE

Zitieren

APA

Jay, C. M., Kerneis, F., Rao, D., Nemunaitis, A., Bognar, E., Wallraven, G., Stanbery, L., Lutz, R., Walter, A., Sarshar, S., & Nemunaitis, J. (2026). In Vivo Assessment of dbDNA GNE wt /bi‐shRNA‐GNE M743T Lipoplex for GNE Myopathy: Improved Potency and Safety. The Journal of Gene Medicine. https://doi.org/10.1002/jgm.70098

Vancouver

Jay CM, Kerneis F, Rao D, Nemunaitis A, Bognar E, Wallraven G, et al. In Vivo Assessment of dbDNA GNE wt /bi‐shRNA‐GNE M743T Lipoplex for GNE Myopathy: Improved Potency and Safety. The Journal of Gene Medicine. 2026. doi:10.1002/jgm.70098

BibTeX
@article{Jay2026,
  author = {Jay, Christopher M and Kerneis, Fabienne and Rao, Donald and Nemunaitis, Alexander and Bognar, Ernest and Wallraven, Gladice and Stanbery, Laura and Lutz, Rebecca and Walter, Adam and Sarshar, Sep and Nemunaitis, John},
  title = {In Vivo Assessment of dbDNA GNE wt /bi‐shRNA‐GNE M743T Lipoplex for GNE Myopathy: Improved Potency and Safety},
  journal = {The Journal of Gene Medicine},
  year = {2026},
  doi = {10.1002/jgm.70098}
}
Kostenlos starten →